BPS804 20mg/Kg + Placebo to 20mg/Kg BPS804
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteopenia
Conditions
Osteopenia, Osteoporosis
Trial Timeline
Jul 1, 2011 → Oct 1, 2013
NCT ID
NCT01406548About BPS804 20mg/Kg + Placebo to 20mg/Kg BPS804
BPS804 20mg/Kg + Placebo to 20mg/Kg BPS804 is a phase 2 stage product being developed by Novartis for Osteopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT01406548. Target conditions include Osteopenia, Osteoporosis.
What happened to similar drugs?
5 of 10 similar drugs in Osteopenia were approved
Approved (5) Terminated (0) Active (5)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01406548 | Phase 2 | Completed |
Competing Products
18 competing products in Osteopenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Teriparatide + Zoledronic Acid | Eli Lilly | Approved | 43 |
| alendronate sodium | Merck | Approved | 43 |
| zoledronic acid | Novartis | Phase 3 | 40 |
| zoledronic acid vs pamidronate | Novartis | Approved | 43 |
| Zoledronic Acid + Placebo | Novartis | Phase 3 | 40 |
| Placebo + ibandronate [Bonviva/Boniva] | Roche | Approved | 43 |
| ibandronate [Bonviva/Boniva] + Placebo | Roche | Phase 3 | 40 |
| Romosozumab + Placebo | Amgen | Phase 1 | 29 |
| Placebo + AMG 167 | Amgen | Phase 1 | 29 |
| AMG 167 + Placebo | Amgen | Phase 1 | 29 |
| Romosozumab + Placebo | Amgen | Phase 1 | 29 |
| Denosumab | Amgen | Phase 3 | 40 |
| Romosozumab + Placebo | Amgen | Phase 1 | 29 |
| Dasatinib 100 Mg Oral Tablet | Novo Nordisk | Phase 2 | 39 |
| RN564 | Pfizer | Phase 1 | 29 |
| risedronate + alendronate | Sanofi | Phase 1 | 29 |
| Menostar (Estradiol, BAY86-5435) + Raloxifene | Bayer | Phase 3 | 37 |
| tibolone + raloxifen | Organon | Approved | 37 |